Hosted on MSN1mon
Novo Nordisk Falls Most on Record After New Weight Drug DisappointsNovo Nordisk’s results for its CagriSema drug ... though it’s only in Phase 1 trials currently. — John Murphy, BI pharma analyst Novo’s CagriSema Data Gives Lilly Upper Hand in Obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback